Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: The C 14-erythromycin breath test and the antipyrine clearance test

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 1, 2012, Pages 125-135

  Michael, M ^a   Cullinane, C ^a   Hatzimihalis, A ^a   O'Kane, C ^a   Milner, A ^a   Booth, R ^b   Schlicht, S ^b   Clarke, S J ^c,d   Francis, P ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c ANZAC Research Institute   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Antipyrine; Docetaxel; Erythromycin breath test; In vivo probes

Indexed keywords

[N METHYL]ERYTHROMYCIN C 14; CARBON DIOXIDE; CYTOCHROME P450; DOCETAXEL; PHENAZONE; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIPYRINE CLEARANCE TEST; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BREATH ANALYSIS; CARBON DIOXIDE TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG SAFETY; ERYTHROMYCIN BREATH TEST; FEBRILE NEUTROPENIA; FEMALE; HUMAN; IN VIVO STUDY; INTERMETHOD COMPARISON; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; MALE; MOLECULAR PROBE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; REACTION TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTIPYRINE; AREA UNDER CURVE; BREATH TESTS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROMYCIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; TAXOIDS;

EID: 84856724309     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1676-y     Document Type: Article

References (45)

1. SD Baker J Verweij GA Cusatis RH van Schaik S Marsh SJ Orwick RM Franke S Hu EG Schuetz V Lamba WA Messersmith AC Wolff MA Carducci A Sparreboom 2009 Pharmacogenetic pathway analysis of docetaxel elimination Clin Pharmacol Ther 85 155 163 18509327 10.1038/clpt.2008.95 1:CAS:528:DC%2BD1MXmt1Cquw%3D%3D
2. SD Baker M Zhao CK Lee J Verweij Y Zabelina JR Brahmer AC Wolff A Sparreboom MA Carducci 2004 Comparative pharmacokinetics of weekly and every-three-weeks docetaxel Clin Cancer Res 10 1976 1983 15041715 10.1158/1078-0432.CCR-0842-03 1:CAS:528:DC%2BD2cXisVGlu7w%3D (Pubitemid 38375556)
3. Baker SD, Ten Tije AJ, Carducci MA, Gelderblom H, Dawkins FW, McGuire WP, Verweij J (2004) Evaluation of CYP3A activity as a predictive covariate for docetaxel clearance. J Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition). 22: Abstr 2006
4. KJ Breen RW Bury IV Calder PV Desmond M Peters ML Mashford 1984 A [14C]phenacetin breath test to measure hepatic function in man Hepatology 4 47 52 6420304 10.1002/hep.1840040108 1:CAS:528:DyaL2cXitVKjtrk%3D (Pubitemid 14185423)
5. R Bruno D Hille A Riva N Vivier WW ten Bokkel Huinnink AT van Oosterom SB Kaye J Verweij FV Fossella V Valero JR Rigas AD Seidman B Chevallier P Fumoleau HA Burris PM Ravdin LB Sheiner 1998 Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer J Clin Oncol 16 187 196 9440742 1:CAS:528:DyaK1cXmsVejtg%3D%3D (Pubitemid 28041598)
6. KA Charles LP Rivory MR Stockler P Beale J Beith M Boyer SJ Clarke 2006 Predicting the toxicity of weekly docetaxel in advanced cancer Clin Pharmacokinet 45 611 622 16719542 10.2165/00003088-200645060-00004 1:CAS:528:DC%2BD28XmvVCmtrs%3D (Pubitemid 44046487)
7. M Danhof A van Zuilen JK Boeijinga DD Breimer 1982 Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time Eur J Clin Pharmacol 21 433 441 7075648 10.1007/BF00542332 1:CAS:528:DyaL38Xhslert7s%3D (Pubitemid 12170404)
8. G Engel U Hofmann H Heidemann J Cosme M Eichelbaum 1996 Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation Clin Pharmacol Ther 59 613 623 8681486 10.1016/S0009-9236(96)90001-6 1:CAS:528:DyaK28XksFemurg%3D (Pubitemid 26233417)
9. FK Engels WJ Loos JM van der Bol P de Bruijn RH Mathijssen J Verweij RA Mathot 2011 Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study Clin Cancer Res 17 353 362 21224369 10.1158/1078-0432.CCR-10-1636 1:CAS:528:DC%2BC3MXmslyqtw%3D%3D
10. GC Farrell L Zaluzny 1984 Accuracy and clinical utility of simplified tests of antipyrine metabolism Br J Clin Pharmacol 18 559 565 6487495 1:CAS:528:DyaL2MXhslSkuw%3D%3D (Pubitemid 14009949)
11. A Felici J Verweij A Sparreboom 2002 Dosing strategies for anticancer drugs: the good, the bad and body-surface area Eur J Cancer 38 1677 1684 12175683 10.1016/S0959-8049(02)00151-X 1:CAS:528:DC%2BD38XmtVSmtb4%3D
12. LA Frassetto S Poon C Tsourounis C Valera LZ Benet 2007 Effects of uptake and efflux transporter inhibition on erythromycin breath test results Clin Pharmacol Ther 81 828 832 17361125 10.1038/sj.clpt.6100148 1:CAS:528: DC%2BD2sXmsF2iurc%3D (Pubitemid 46788293)
13. J Gartzke H Jager 1991 The determination of antipyrine elimination in saliva by liquid chromatography J Pharm Biomed Anal 9 977 979 1822222 10.1016/0731-7085(91)80033-6 1:CAS:528:DyaK38XktVemtr8%3D
14. BC Goh SC Lee LZ Wang L Fan JY Guo J Lamba E Schuetz R Lim HL Lim AB Ong HS Lee 2002 Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies J Clin Oncol 20 3683 3690 12202670 10.1200/JCO.2002.01.025 1:CAS:528: DC%2BD38XntVynsrc%3D (Pubitemid 34983229)
15. A Grieco C Barone P Coletta R Castellano E Ragazzoni A Cassano A Astone G Gambassi 1992 Antipyrine metabolism in patients with liver metastases from colorectal cancer Cancer 70 1477 1482 1515999 10.1002/1097-0142(19920915)70: 6<1477::AID-CNCR2820700605>3.0.CO;2-T 1:CAS:528:DyaK3sXjs1yjug%3D%3D
16. A Grieco R Castellano A Matera S Marcoccia P Di Rocco E Ragazzoni FM Vecchio G Gasbarrini 1998 Antipyrine clearance in chronic and neoplastic liver diseases: a study of 518 patients J Gastroenterol Hepatol 13 460 466 9641640 10.1111/j.1440-1746.1998.tb00668.x 1:CAS:528:DyaK1cXktVCjt7s%3D (Pubitemid 28258943)
17. H Gurney 1996 Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative J Clin Oncol 14 2590 2611 8823340 1:CAS:528:DyaK28XlvVGisLg%3D (Pubitemid 26300128)
18. DL Gustafson ME Long JA Zirrolli MW Duncan SN Holden AS Pierson SG Eckhardt 2003 Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay Cancer Chemother Pharmacol 52 159 166 12759775 10.1007/s00280-003-0622-z 1:CAS:528:DC%2BD3sXlsVylsbk%3D (Pubitemid 37041350)
19. Hilli J, Sailas L, Jyrkkio S, Pyrhonen S, Laine K (2010) NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer. Cancer Chemother Pharmacol (Epub ahead of print)
20. J Hirth PB Watkins M Strawderman A Schott R Bruno LH Baker 2000 The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance Clin Cancer Res 6 1255 1258 10778948 1:CAS:528:DC%2BD3cXjtVOqtrw%3D (Pubitemid 30226205)
21. AC Hooker AJ Ten Tije MA Carducci J Weber E Garrett-Mayer H Gelderblom WP McGuire J Verweij MO Karlsson SD Baker 2008 Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements Clin Pharmacol Ther 84 111 118 18183036 10.1038/sj.clpt.6100476 1:CAS:528:DC%2BD1cXnt1KqsLo%3D (Pubitemid 351861492)
22. A Hurria MT Fleming SD Baker WK Kelly K Cutchall K Panageas J Caravelli H Yeung MG Kris J Gomez VA Miller G D'Andrea HI Scher L Norton C Hudis 2006 Pharmacokinetics and toxicity of weekly docetaxel in older patients Clin Cancer Res 12 6100 6105 17062686 10.1158/1078-0432.CCR-06-0200 1:CAS:528: DC%2BD28XhtFWhsbnK (Pubitemid 44703775)
23. D Kurnik AJ Wood GR Wilkinson 2006 The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity Clin Pharmacol Ther 80 228 234 16952489 10.1016/j.clpt.2006.06.002 1:CAS:528:DC%2BD28XptFCgu7o%3D (Pubitemid 44301092)
24. K Lown J Kolars K Turgeon R Merion SA Wrighton PB Watkins 1992 The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease Clin Pharmacol Ther 51 229 238 1544283 10.1038/clpt.1992.17 1:STN:280:DyaK387otlCitA%3D%3D
25. M Mahmoud R Abdel-Kader M Hassanein S Saleh S Botros 2007 Antipyrine clearance in comparison to conventional liver function tests in hepatitis C virus patients Eur J Pharmacol 569 222 227 17628532 10.1016/j.ejphar.2007.04.061 1:CAS:528:DC%2BD2sXovFOjs7g%3D (Pubitemid 47214559)
26. F Marre GJ Sanderink G de Sousa C Gaillard M Martinet R Rahmani 1996 Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans Cancer Res 56 1296 1302 8640817 1:CAS:528: DyaK28XhsFGntro%3D (Pubitemid 26080972)
27. M Nishio M Matsuda F Ohyanagi Y Sato S Okumura D Tabata A Morikawa K Nakagawa T Horai 2005 Antipyrine test predicts pharmacodynamics in docetaxel and cisplatin combination chemotherapy Lung Cancer 49 245 251 16022919 10.1016/j.lungcan.2005.02.007 (Pubitemid 40966754)
28. Nishio MM, M. Karato, A. Sato, Y. Okumura, S. Nakagawa, K. Tabata, D. Morikawa, A, Horai, T (2001) Positive correlation between elimination rate of antipyrine mediated by CYPs and pharmacokinetic parameters of paclitaxel in combination chemotherapy with carboplatin in non-small cell lung cancer patients. Proc Am Soc Clin Oncol 20:445 (Abstr)
29. S O'Reilly E Rowinsky W Slichenmyer RC Donehower A Forastiere D Ettinger TL Chen S Sartorius K Bowling J Smith A Brubaker B Lubejko V Ignacio LB Grochow 1996 Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function J Natl Cancer Inst 88 817 824 8637048 10.1093/jnci/88.12.817 (Pubitemid 26191135)
30. I Olver M Davy D Luftner SH Park M Egorin A Ellis L Webster 2001 A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer Cancer Chemother Pharmacol 48 109 114 11561776 10.1007/s002800000263 1:CAS:528:DC%2BD3MXltlyqtLs%3D (Pubitemid 32710221)
31. K Orzechowska-Juzwenko A Wiela A Cieslinska E Roszkowska 1987 Metabolic efficiency of the liver in patients with breast cancer as determined by pharmacokinetics of phenazone Cancer 59 1607 1610 3828961 10.1002/1097- 0142(19870501)59:9<1607::AID-CNCR2820590914>3.0.CO;2-3 1:STN:280:DyaL2s7lvFWktg%3D%3D (Pubitemid 17060104)
32. R Preiss M Matthias R Sohr B Brockmann H Huller 1987 Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver J Cancer Res Clin Oncol 113 593 598 2824523 10.1007/BF00390872 1:STN:280:DyaL1c%2FlvFahtg%3D%3D (Pubitemid 18044749)
33. F Puisset J Alexandre JM Treluyer V Raoul H Roche F Goldwasser E Chatelut 2007 Clinical pharmacodynamic factors in docetaxel toxicity Br J Cancer 97 290 296 17595656 10.1038/sj.bjc.6603872 1:CAS:528:DC%2BD2sXotlSgtrw%3D (Pubitemid 47196745)
34. LP Rivory KA Slaviero JM Hoskins SJ Clarke 2001 The erythromycin breath test for the prediction of drug clearance Clin Pharmacokinet 40 151 158 11327195 10.2165/00003088-200140030-00001 1:CAS:528:DC%2BD3MXjsVWmtro%3D (Pubitemid 32324447)
35. Rizzo JD, Villalona-Calero M, Garrison M, Schwartz G, Molpus K, Monroe P, Tolcher A, Hammond L, Rowinsky EK A pharmacologic and metabolic study of docetaxel (D) administered on a continuous weekly schedule in patients with advanced solid tumors. Proc Am Soc Clin Oncol 22:651 (Abstr)
36. AF Schott JM Rae KA Griffith DF Hayes V Sterns LH Baker 2006 Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme Cancer Chemother Pharmacol 58 129 135 16283312 10.1007/s00280-005-0132-2 1:CAS:528:DC%2BD28XjslGjtr8%3D
37. EG Schuetz K Yasuda K Arimori JD Schuetz 1998 Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene Arch Biochem Biophys 350 340 347 9473310 10.1006/abbi.1997.0537 1:CAS:528:DyaK1cXhtVWgsbs%3D (Pubitemid 28368662)
38. KA Slaviero SJ Clarke AJ McLachlan EY Blair LP Rivory 2004 Population pharmacokinetics of weekly docetaxel in patients with advanced cancer Br J Clin Pharmacol 57 44 53 14678339 10.1046/j.1365-2125.2003.01956.x 1:CAS:528:DC%2BD2cXotlOjug%3D%3D (Pubitemid 38067949)
39. E Tanaka DD Breimer 1997 In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease J Clin Pharm Ther 22 237 249 9548204 10.1046/j.1365-2710.1997.10875108.x 1:CAS:528:DyaK1cXitleisrc%3D (Pubitemid 28098714)
40. AJ ten Tije J Verweij MA Carducci W Graveland T Rogers T Pronk MP Verbruggen F Dawkins SD Baker 2005 Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly J Clin Oncol 23 1070 1077 15718305 10.1200/JCO.2005.03.082 1:CAS:528:DC%2BD2MXitl2gtb8%3D (Pubitemid 46202261)
41. A Tran V Jullien J Alexandre E Rey F Rabillon V Girre V Dieras G Pons F Goldwasser JM Treluyer 2006 Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms Clin Pharmacol Ther 79 570 580 16765145 10.1016/j.clpt.2006.02.003 1:CAS:528:DC%2BD28Xltl2msrc%3D (Pubitemid 43833447)
42. PB Watkins SA Murray LG Winkelman DM Heuman SA Wrighton PS Guzelian 1989 Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients J Clin Invest 83 688 697 2913056 10.1172/JCI113933 1:CAS:528:DyaL1MXhsFShsrs%3D (Pubitemid 19061193)
43. LK Webster AG Ellis JF Bishop 1993 Effect of toremifene on antipyrine elimination in the isolated perfused rat liver Cancer Chemother Pharmacol 31 319 323 8422697 10.1007/BF00685678 1:CAS:528:DyaK3sXhvVaksbs%3D (Pubitemid 23029158)
44. HS Winchell H Stahelin N Kusubov B Slanger M Fish M Pollycove JH Lawrence 1970 Kinetics of CO2-HCO3 minus in normal adult males J Nucl Med 11 711 715 5490399 1:CAS:528:DyaE3MXht1amu7s%3D
45. N Yamamoto T Tamura Y Kamiya I Sekine H Kunitoh N Saijo 2000 Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol J Clin Oncol 18 2301 2308 10829051 1:CAS:528:DC%2BD3cXktlagsbk%3D (Pubitemid 30350223)